Click on the name of the lead author of a reference to view it:
Aylward et al. Temporal trends in human TCDD body burden: Decrease over three decades, implications for exposure levels. J Exposure Anal Environ Epidemiol12: 319−328
Berenson, J.R., Anderson, K.C., Audell, R.A., Boccia, R.V., Coleman, M., Dimopoulos, M.A., Drake, M.T., Fonseca, R., Harousseau, J.-L., Joshua, D., Lonial, S., Niesvizky, R., Palumbo, A., Roodman, G.D., San-Miguel, J.F., Singhal, S., Weber, D.M., Zangari, M., Wirtschafter, E., Yellin, O. and Kyle, R.A. (2010), Monoclonal gammopathy of undetermined significance: a consensus statement. British Journal of Haematology, 150: 28-38.
Bianchi et al. Impact of Optimal Follow-up of Monoclonal Gammopathy of Undetermined Significance on Early Diagnosis and Prevention of Myeloma-related Complications. Blood. 2010 Sep 23; 116(12): 2019–2025.
Bida JP, Kyle RA, Therneau TM, Melton LJ 3rd, Plevak MF, Larson DR, Dispenzieri A, Katzmann JA, Rajkumar SV. Disease associations with monoclonal gammopathy of undetermined significance: a population-based study of 17,398 patients. Mayo Clin Proc. 2009 Aug;84(8):685-93.
Blade et al. Pathogenesis and progression of monoclonal gammopathy of undetermined significance. Leukemia. 2008 Sep;22(9):1651-7.
Brawley OW. Some Thoughts on Exposure to the World Trade Center Wreckage and Cancer. JAMA Oncol. 2018;4(6):775–776.
Berenson JR, Anderson KC, Audell RA, Boccia RV, Coleman M, Dimopoulos MA, Drake MT, Fonseca R, Harousseau JL, Joshua D, Lonial S, Niesvizky R, Palumbo A, Roodman GD, San-Miguel JF, Singhal S, Weber DM, Zangari M, Wirtschafter E, Yellin O, Kyle RA. Monoclonal gammopathy of undetermined significance: a consensus statement. Br J Haematol. 2010 Jul;150(1):28-38.
Brown LM, Gridley G, Check D, Landgren O. Risk of multiple myeloma and monoclonal gammopathy of undetermined significance among white and black male United States veterans with prior autoimmune, infectious, inflammatory, and allergic disorders. Blood. 2008 Apr 1;111(7):3388-94.
Bumma et al. Incidence of Monoclonal Gammopathy of Undetermined Significance (MGUS) and Subsequent Transformation to Multiple Myeloma (MM) and Effect of Exposure to Agent Orange (AO) : A Single Center Experience from VA Detroit. Blood 2017; 130 (Supplement 1): 5383. (PDF version)
Bumma et al. Effect of Exposure to Agent Orange on the Risk of Monoclonal Gammopathy and Subsequent Transformation to Multiple Myeloma: A Single-Center Experience From the Veterans Affairs Hospital, Detroit. Clin Lymphoma Myeloma Leuk. 2020 May;20(5):305-311.
Callander et al. Previous Agent Orange Exposure Is Correlated with Worse Outcome in Patients with Multiple Myeloma (MM). Blood 2015; 126 (23): 4194.
Cypel et al. Herbicide Exposure, Vietnam Service, and Hypertension Risk in Army Chemical Corps Veterans. J Occup Environ Med. 2016 Nov;58(11):1127-1136. (PDF version)
Dispenzieri A, Katzmann JA, Kyle RA, et al. Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study [published correction appears in Lancet. 2010 Jul 31;376(9738):332]. Lancet. 2010;375(9727):1721-1728.
Eskenazi B, Mocarelli P, Warner M, et al. Relationship of serum TCDD concentrations and age at exposure of female residents of Seveso, Italy. Environ Health Perspect. 2004;112(1):22-27.
Falco. Agent Orange Linked to Increased Risk of MGUS in Some Vietnam Veterans. Memorial Sloan Kettering Cancer Center. In the News.
Fanning SR, Besa EC. Monoclonal Gammopathies of Undetermined Significance Treatment & Management. Medscape. Feb 11, 2020
Fonseca R, Hayman S. Waldenström macroglobulinaemia. Br J Haematol. 2007 Sep;138(6):700-20.
Gertz, MA. Waldenström macroglobulinemia treatment algorithm 2018. Blood Cancer J. 8, 40 (2018). (PDF version)
Go RS, and Doyle LM. A monoclonal gammopathy in search of clinical significance: 57 years later. Blood 2009; 114 (11): 2355–2356. (PDF version)
Go et al. Determining the clinical significance of monoclonal gammopathy of undetermined significance: a SEER-Medicare population analysis. Clin Lymphoma Myeloma Leuk. 2015 March ; 15(3): 177–186.e4.
Goldin LR, McMaster ML, Caporaso NE (2013). Precursors to lymphoproliferative malignancies. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 22(4), 533–539.
Gonzalez-Lugo JD, Bachier-Rodriguez L, Goldfinger M, Shastri A, Sica RA, Gritsman K, Mehta V, Kabarriti R, Goel S, Verma A, Braunschweig I, Kornblum N, Mantzaris I. A case series of Monoclonal Gammopathy of Undetermined Significance and COVID-19. Br J Haematol. 2020 Aug;190(3):e130-e133. (PDF version)
Jain A, Ramasamy K. Potential ‘significance’ of monoclonal gammopathy of ‘undetermined significance’ during COVID-19 pandemic. Blood Cells Mol Dis. 2020;85:102481. doi:10.1016/j.bcmd.2020.102481. (PDF version)
Kapoor P, Ansell SM, Fonseca R, Chanan-Khan A, Kyle RA, Kumar SK, Mikhael JR, Witzig TE, Mauermann M, Dispenzieri A, Ailawadhi S, Stewart AK, Lacy MQ, Thompson CA, Buadi FK, Dingli D, Morice WG, Go RS, Jevremovic D, Sher T, King RL, Braggio E, Novak A, Roy V, Ketterling RP, Greipp PT, Grogan M, Micallef IN, Bergsagel PL, Colgan JP, Leung N, Gonsalves WI, Lin Y, Inwards DJ, Hayman SR, Nowakowski GS, Johnston PB, Russell SJ, Markovic SN, Zeldenrust SR, Hwa YL, Lust JA, Porrata LF, Habermann TM, Rajkumar SV, Gertz MA, Reeder CB. Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016. JAMA Oncol. 2017 Sep 1;3(9):1257-1265.
Karp M, Giannopoulos K. Antigen stimulation in the development of chronic lymphocytic leukemia. Postepy Hig Med Dosw (Online). 2013 Dec 5;67:1204-13.
Khouri J et al. Update on the Diagnosis and Treatment of POEMS (Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Gammopathy, and Skin Changes) Syndrome: A Review. JAMA Oncol. 2021;7(9):1383–1391. (PDF version)
Kristinsson SY. Screening for monoclonal gammopathy of undetermined significance: A population-based randomized clinical trial. 2016. (PDF version)
Kristinsson SY, Björkholm M, Andersson TM, Eloranta S, Dickman PW, Goldin LR, Blimark C, Mellqvist UH, Wahlin A, Turesson I, Landgren O. Patterns of survival and causes of death following a diagnosis of monoclonal gammopathy of undetermined significance: a population-based study. Haematologica. 2009 Dec;94(12):1714-20.
Kumar et al. Outcome after autologous stem cell transplantation for multiple myeloma in patients with preceding plasma cell disorders. Br J Haematol. 2008 Apr;141(2):205-11.
Kyle RA, Larson DR, Therneau TM, et al. Long-term follow-up of monoclonal gammopathy of undetermined significance. N Engl J Med. 2018;378(3):241-9.
Kyle RA, Therneau TM, Rajkumar SV, Remstein ED, Offord JR, Larson DR, Plevak MF, Melton LJ 3rd. Long-term follow-up of IgM monoclonal gammopathy of undetermined significance. Blood. 2003 Nov 15;102(10):3759-64.
Landgren O, Kyle RA. Multiple myeloma, chronic lymphocytic leukaemia and associated precursor diseases. Br J Haematol. 2007 Dec;139(5):717-23.
Landgren O, Kyle RA, Rajkumar V. Response: Multiple myeloma is universally preceded by a prolonged premalignant stage: novel clinical insights and future directions. Blood 2009; 114 (11): 2356–2357.
Landgren O. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: biological insights and early treatment strategies. Hematology Am Soc Hematol Educ Program 2013; 2013 (1): 478–487.
Landgren et al. Agent Orange Exposure and Monoclonal Gammopathy of Undetermined Significance: An Operation Ranch Hand Veteran Cohort Study. JAMA Oncol. 2015;1(8):1061–1068 (PDF version) (Interview with lead author) (Editorial comment)
Landgren O, Zeig-Owens R, Giricz O, et al. Multiple Myeloma and Its Precursor Disease Among Firefighters Exposed to the World Trade Center Disaster. JAMA Oncol. 2018;4(6):821–827.
Landgren O, Hofmann JN, McShane CM, Santo L, Hultcrantz M, Korde N, Mailankody S, Kazandjian D, Murata K, Thoren K, Ramanathan L, Dogan A, Rustad E, Lu SX, Akhlaghi T, Kristinsson SY, Björkholm M, Devlin S, Purdue MP, Pfeiffer RM, Turesson I. Association of Immune Marker Changes With Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma. JAMA Oncol. 2019 Jul 18;5(9):1293–301.
A Patient with Abnormal Kidney Function and a Monoclonal Light Chain in the Urine.
Martinez et al. Agent Orange Exposure and Dementia Diagnosis in US Veterans of the Vietnam Era. JAMA Neurol. Published online January 25, 2021. (PDF version) (Interview with lead author) (Comment by VA) (Reply)
Merlini G, Stone MJ. Dangerous small B-cell clones. Blood 2006; 108 (8): 2520–2530.
Merlini G, Palladini G. Differential diagnosis of monoclonal gammopathy of undetermined significance. Hematology Am Soc Hematol Educ Program 2012; 2012 (1): 595–603.
Mikhael J. ASK THE HEMATOLOGIST: A Diagnostic Approach to Patients with an IgM Monoclonal Protein. The Hematologist (2014) 11 (5).
Milbrath MO, Wenger Y, Chang CW, Emond C, Garabrant D, Gillespie BW, Jolliet O. Apparent Half-Lives of Dioxins, Furans, and Polychlorinated Biphenyls as a Function of Age, Body Fat, Smoking Status, and Breast-Feeding. Environmental Health Perspectives. Vol. 117, No. 3. 1 March 2009.
Morra E, Cesana C, Klersy C et al. Clinical characteristics and factors predicting evolution of asymptomatic IgM monoclonal gammopathies and IgM-related disorders. Leukemia 18, 1512–1517 (2004).
Munshi NC. Association of Agent Orange With Plasma Cell Disorder: Further Evidence. JAMA Oncol. 2015;1(8):1035–1036.
Paludo J, Ansell SM. Advances in the understanding of IgM monoclonal gammopathy of undetermined significance. F1000Res. 2017 Dec 18;6:2142.
Rajkumar SV, Kyle RA, Therneau TM, Melton LJ 3rd, Bradwell AR, Clark RJ, Larson DR, Plevak MF, Dispenzieri A, Katzmann JA. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood. 2005 Aug 1;106(3):812-7.
Rajkumar SV. Prevention of progression in monoclonal gammopathy of undetermined significance. Clin Cancer Res. 2009 Sep 15;15(18):5606-8.
Rajkumar SV. Clinical course and management of monoclonal gammopathy of undetermined significance. UpToDate. Sep 13, 2019. (PDF version)
Rison RA, Beydoun SR. Paraproteinemic neuropathy: a practical review. BMC Neurol 16, 13 (2016).
Sigurdardottir et al. The Role of Diagnosis and Clinical Follow-up of Monoclonal Gammopathy of Undetermined Significance on Survival in Multiple Myeloma. JAMA Oncol. 2015;1(2):168–174.
The JAMA Network. Agent_Orange_Exposure_and_Monoclonal_Gammopathy_J
AMA_Oncology (1).mp3. Transcribed 17-Nov-2017. (PDF version)
Therneau TM, Kyle RA, Melton LJ 3rd, Larson DR, Benson JT, Colby CL, Dispenzieri A, Kumar S, Katzmann JA, Cerhan JR, Rajkumar SV. Incidence of monoclonal gammopathy of undetermined significance and estimation of duration before first clinical recognition. Mayo Clin Proc. 2012 Nov;87(11):1071-9.
Thordardottir M, Lindqvist EK, Lund SH, et al. Obesity and risk of monoclonal gammopathy of undetermined significance and progression to multiple myeloma: a population-based study. Blood Adv. 2017;1(24):2186-2192. Published 2017 Nov 1. doi:10.1182/bloodadvances.2017007609.
Thorsteinsdottir S, Lund SH, Lindqvist EK, Thordardottir M, Sigurdsson G, Costello R, Burton D, Steingrimsdottir H, Gudnason V, Eiriksdottir G, Siggeirsdottir K, Harris TB, Landgren O, Kristinsson SY. Bone disease in monoclonal gammopathy of undetermined significance: results from a screened population-based study. Blood Adv. 2017 Dec 21;1(27):2790-2798.
Treon SP, Cao Y, Xu L, Yang G, Liu X, Hunter ZR. Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia. Blood. 2014 May 1;123(18):2791-6.
Tsai HT, Caporaso NE, Kyle RA, Katzmann JA, Dispenzieri A, Hayes RB, Marti GE, Albitar M, Ghia P, Rajkumar SV, Landgren O. Evidence of serum immunoglobulin abnormalities up to 9.8 years before diagnosis of chronic lymphocytic leukemia: a prospective study. Blood. 2009 Dec 3;114(24):4928-32.
Turesson I, Kovalchik SA, Pfeiffer RM, Kristinsson SY, Goldin LR, Drayson MT, Landgren O. Monoclonal gammopathy of undetermined significance and risk of lymphoid and myeloid malignancies: 728 cases followed up to 30 years in Sweden. Blood. 2014 Jan 16;123(3):338-45.
US Department of Veterans Affairs. Veterans’ Diseases Associated with Agent Orange
Varettoni M, Zibellini S, Arcaini L, Boveri E, Rattotti S, Pascutto C, Mangiacavalli S, Gotti M, Pochintesta L, Paulli M, Cazzola M. MYD88 (L265P) mutation is an independent risk factor for progression in patients with IgM monoclonal gammopathy of undetermined significance. Blood. 2013 Sep 26;122(13):2284-5.
Weiss BM, Hebreo J, Cordaro D, Roschewski MJ, Abbott KC, Olson SW. Monoclonal Gammopathy of Undetermined Significance (MGUS) Precedes the Diagnosis of AL Amyloidosis by up to 14 Years. Blood 2011; 118 (21): 1827.
Weiss BM, Hebreo J, Cordaro DV, Roschewski MJ, Baker TP, Abbott KC, Olson SW. Increased serum free light chains precede the presentation of immunoglobulin light chain amyloidosis. J Clin Oncol. 2014 Sep 1;32(25):2699-704. (PDF version)